J. Bussolari

发表

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

J. Tabernero, J. Soria, R. Dienstmann, 2014 .

COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETNOID-X RECEPTOR MODULATORS CROSS REFERENCE TO RELATED APPLICATIONS

J. Bussolari, R. Severino, 2017 .

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

E. Vellenga, D. Steensma, P. Fenaux, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

E. Vellenga, D. Steensma, P. Fenaux, 2018, Blood.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

D. Niederwieser, R. Hoffman, A. Vannucchi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

J. Blay, P. Hammerman, A. Italiano, 2016 .

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors

G. Baerlocher, Fei Huang, J. Bussolari, 2020, International journal of molecular sciences.

S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

E. Vellenga, D. Steensma, P. Fenaux, 2019, HemaSphere.

Parallel synthesis of 2-alkoxy and 2-acyloxyphenylpropyl amides and amines using dihydrocoumarins as versatile synthons. Application of a novel resin quench-capture method

J. Bussolari, D. Combs, Diana C. Rehborn, 1999 .

Synthesis and anti-HIV evaluation of 2',3'-dideoxy imidazo- and nu-triazolo[4,5-d]pyridazine nucleosides.

R. P. Panzica, J. Bussolari, 1999, Bioorganic & medicinal chemistry.

Preparation and reactions of chiral propargylic amines

P. Dorff, G. Martinelli, J. Hauske, 1992 .

A New Substrate for the Biginelli Cyclocondensation: Direct Preparation of 5-Unsubstituted 3,4-Dihydropyrimidin-2(1H)-ones from a β-Keto Carboxylic Acid

P. McDonnell, J. Bussolari, Patricia A. McDonnell, 2000 .

Synthesis and biological evaluation of N4-substituted imidazo- and v-triazolo[4,5-d]pyridazine nucleosides.

J. Stoeckler, S. Chen, R. P. Panzica, 1993, Journal of medicinal chemistry.

The synthesis and biological evaluation of 4-p-nitrobenzylthio-v-triazolo[4,5-d]pyridazine and imidazo[4,5-d]pyridazine ribosides as potential nucleoside transport inhibitors.

J. Stoeckler, R. P. Panzica, J. Bussolari, 1996, Bioorganic & medicinal chemistry.

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

D. Niederwieser, R. Hoffman, A. Reiter, 2018, Blood.

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

A. Vannucchi, J. Mascarenhas, R. Komrokji, 2021, Annals of Hematology.

2,5-Diketopiperazines, new chiral auxiliaries for asymmetric Diels-Alder reactions

T. Le, W. Murray, J. Bussolari, 1997 .

Abstract 1256: JNJ-74856665, a novel DHODH inhibitor, mediates potent anti-leukemic activity and differentiationin vitroandin vivo

E. Jacoby, T. Bush, S. Kuduk, 2021, Experimental and Molecular Therapeutics.

Addition of Acrylamide to Amino Aldehydes to Generate Non-Baylis-Hillman Adducts. Formation of Novel N-Acylhemiaminals

W. Murray, K. Beers, P. McDonnell, 1998 .

Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database

M. Mehra, R. Potluri, S. Mundle, 2016 .

PS1456 FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA

A. Vannucchi, J. Mascarenhas, R. Komrokji, 2019, HemaSphere.